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Abstract. We assessed the effect of anti-filarial treatment (diethylcarbamazine, DEC) on HIV load, CD4%, and
CD4/CD8 ratio in HIV-positive individuals with and without infection with the filarial parasite Wuchereria bancrofti in
a randomized, double-blind, placebo-controlled cross-over trial. The study was conducted in Tanga Region, Tanzania,
in 2002 and involved 27 adults. A significant decrease in HIV load (54%) and an insignificant increase in CD4% were
observed in the HIV-positive individuals with filarial co-infection at 12 weeks after treatment. HIV load and CD4% both
increased, although not statistically significantly, in the HIV-positive individuals without filarial infection. The findings
suggest that DEC affected HIV load through its effect on the filarial infection rather than through a direct (pharma-
codynamic) effect on HIV. Global efforts to control lymphatic filariasis by annual mass treatment with DEC may have
a beneficial effect on the HIV/AIDS epidemic in areas where HIV and lymphatic filariasis co-exist.
INTRODUCTION
The high prevalence of HIV and parasite infections in sub-
Saharan Africa results in large geographical overlaps and
thereby potential for interaction between these two types of
infections in co-infected individuals. Parasites, helminths in
particular, may increase susceptibility to HIV and contribute
to a more rapid progression toward AIDS.1–3 Helminth-
induced immune activation may be an underlying mechanism,
as helminth infections are associated with increased viral rep-
lication.3 Th1–Th2 cross-regulation is likely to play a role in
this interaction. Helminth infections are commonly associated
with an upregulated Th2 response. This seems to prevent
production of Th1-related cytokines and cytotoxic T-cell ac-
tivity,1,4 which play a central role in the immunologic combat
against HIV. HIV virus may furthermore replicate more rap-
idly in Th2 cells than in Th1 cells,5 and a significant level of
replication seems to occur in eosinophils in individuals with
helminth-induced eosinophilia.6 Treatment of helminth infec-
tions is thus likely to be particularly beneficial to HIV pa-
tients and has been found to be associated with a significant
decrease in HIV plasma load.7 However, it has also been
observed that helminth infections were not associated with
faster progression of HIV disease, and it was suggested that
anthelminthic therapy may not slow down HIV progression in
co-infected individuals.8 Apart from helminth infections,
some protozoan infections interact with HIV. Thus, malaria
has been shown to be an important factor in promoting the
spread of HIV in sub-Saharan Africa.9
We previously examined the cross-sectional relationship
between subclinical HIV, lymphatic filariasis (Wuchereria
bancrofti infection), and other parasitoses (Plasmodium fal-
ciparum, Ascaris lumbricoides, Trichuris trichiura, and hook-
worm infections) among 858 adults in Tanga Region, north-
eastern Tanzania.10 A significant positive association was ob-
served between HIV and W. bancrofti infection and between
HIV and P. falciparum infection. By contrast, HIV and hook-
worm infection were negatively associated. A more detailed
immunologic study carried out in a subpopulation of 59 indi-
viduals, however, could not provide clear evidence for an
interaction between HIV and W. bancrofti infection.11
In the present study, we looked further into the association
between HIV and W. bancrofti infection, by analyzing the
effect of diethylcarbamazine (DEC) treatment of W. bancrofti
on HIV infection in HIV-positive individuals with W. ban-
crofti co-infection and compared this with the effect in HIV-
positive individuals without filarial co-infection.
MATERIALS AND METHODS
Study population and study design. The study was con-
ducted to assess and compare the effect of DEC on viral load,
CD4%, and CD4/CD8 ratio in HIV-positive individuals with
or without W. bancrofti co-infection in a randomized, double-
blind, placebo-controlled cross-over trial. The study was car-
ried out in May–November 2002 in 5 villages (Mwahako,
Mwakidila, Pongwe South, Kakindu, and Jitengeni) in Tanga
Region, northeastern Tanzania. As part of a cross-sectional
study on the association between HIV, lymphatic filariasis,
and other parasitic infections, 858 adults (18–70 years) were
tested for HIV (antibodies), lymphatic filariasis (W. bancrofti
circulating filarial antigens, CFA), malaria parasites, and in-
testinal helminth eggs.10 Pre- and post-test counseling was
provided by the Tanga AIDS Working Group, a local NGO.
The 858 individuals constituted the source of study individu-
als for further detailed investigations on HIV and filariasis
interactions.
Thirty-four individuals were willing to participate in the
current study and met the inclusion criteria of being 1) HIV-
positive and 2) without obvious clinical manifestations of HIV
and/or W. bancrofti infection. The study individuals were ran-
domly assigned to receive DEC or placebo at the beginning of
the study, and the opposite treatment was given 12 weeks
later (Figure 1). Venous blood was collected at baseline and
at 1, 12, 13, and 24 weeks after the first round of treatment.
Seven of the 34 participants did not complete all follow-up
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examinations and were therefore excluded from the analyses.
There was no difference in age, sex, or infections between
those lost to follow-up and those who remained in the study.
Data from 27 individuals are analyzed. We tested the hypoth-
esis that DEC treatment would 1) reduce the viral load, 2)
increase the CD4%, 3) increase the CD4/CD8 ratio, and 4)
affect HIV-positive individuals with or without W. bancrofti
co-infection differently. Research clearance to conduct the
study was obtained from the Medical Research Coordinating
Committee of the National Institute for Medical Research in
Tanzania, and the study was approved by the Danish National
Committee on Biomedical Research Ethics.
Treatment with diethylcarbamazine (DEC). The 34 study
participants were treated with DEC either at the beginning of
the study or after 12 weeks. The drug was administered as a
single dose of 6 mg/kg body weight, which is the yearly dose
given for transmission control of lymphatic filariasis. The tab-
lets were prepared specifically for this study by a manufac-
turer (Almega, Ringsted, Denmark); 50-mg DEC tablets and
corresponding placebo tablets were supplied. The identical
DEC and placebo tablets were packed in containers with dif-
ferent color codes (“red” or “blue”). Individuals were ran-
domized (1:1) to receive treatment in the order of “red” fol-
lowed by “blue” or “blue” followed by “red” by using a list of
random numbers.12 The selected study participants were
listed and numbered from 1 to 34, and the first 17 numbers
(between 1 and 34) encountered in the table (when starting
on a randomly chosen figure) were assigned to receive treat-
ment in the order red–blue, and the remaining 17 received
treatment in the order blue–red. All study personnel and par-
ticipants were blinded to treatment assignment throughout
the study.
Venous blood samples. At each sampling time, 25 mL of
venous blood (20 mL heparinized and 5 mL non-heparinized)
was collected from each study participant. The blood was
transferred in a cool box to the field laboratory. The 5 mL of
nonheparinized blood was left overnight at 4°C to clot. The
serum was collected the following day and kept at −80°C until
used for quantitative determination of HIV load and CFA
intensity. The 20 mL of heparinized blood was used for iso-
lation of peripheral blood mononuclear cells (PBMCs) and
for cell culturing, separation of plasma, hemoglobin measure-
ments, and preparation of blood slides for further immuno-
logic studies.
Circulating filarial antigen (CFA). The W. bancrofti CFA
status was determined in the field by use of the NOW immu-
nochromatographic test (ICT) for filariasis (Binax, Scarbor-
ough, ME), a rapid, qualitative immunodiagnostic test, as de-
FIGURE 1. Study profile showing details of treatment with diethylcarbamazine (DEC) and placebo. Losses to follow-up were due mainly to
participants’ wish to withdraw from the study or absence at follow-up. HIV+, HIV-positive individuals; CFA+, individuals positive for W. bancrofti
CFA; CFA−, individuals negative for W. bancrofti CFA. *For HIV load analyses, only 5 were analyzed because the HIV RNA could not be
amplified from 1 sample.
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scribed previously.10 The intensity of CFA was later quanti-
fied in serum using the TropBio ELISA test kit (TropBio Pty.
Ltd., Townsville, Australia). Manufacturers’ procedures were
followed, and all tests were carried out in duplicate. Serum
samples with a mean optical density (OD) value > standard 2
(32 antigen units) were considered positive. Most positive
samples had a mean OD value  that of the highest standard
(standard 7  32,000 antigen units). These were subsequently
diluted 1:10 and retested. Samples with a mean OD value 
that of the highest standard after dilution (N  11) were
assigned a value of 320,000 antigen units (corresponding to
32,000 antigen units multiplied by the dilution factor 10).
Assessment of HIV infection. HIV status was determined
in the field by 2 different rapid tests (both detecting antibod-
ies to HIV 1 and 2), as described previously.9 The HIV load
in samples from individuals tested positive in both rapid tests
(discrepancies did not occur) was quantified using a modifi-
cation of an in-house developed reverse-transcriptase PCR.13
HIV RNA was isolated from 125 L of serum. All samples
were analyzed in 2 independent extractions and runs. Samples
with discordant results (discrepancy > 0.5 log) were retested
in duplicate. The limit of detection was 40 genome equiva-
lents (geq)/mL.
Staining and counting of CD4 and CD8 T cells. An immu-
noalkaline (IA) phosphatase method was used for staining
and counting of CD4 and CD8 T cells.14–16 In brief, 2 thin
smears from each patient underwent immunocytochemical la-
beling with monoclonal antibodies against CD4 and CD8 re-
ceptors, respectively. The strengthened (by a secondary anti-
body conjugated to biotin and an avidin–biotin complex con-
jugated to alkaline phosphatase, both from DakoCytomation,
Carpinteria, CA) antigen/antibody binding was visualized as a
reddish-stained ring around the lymphocyte nucleus by add-
ing a substrate containing New Fuchsin (fuchsin + substrate–
chromogen system, DakoCytomation). Stained CD4 and CD8
cells were counted among 200 lymphocytes, and the CD4%
and the CD4/CD8 ratio were estimated. The procedure fol-
lowed the instructions given by a WHO laboratory manual for
characterization of T-cell subsets in peripheral blood.17
Examination for malaria and intestinal helminths. Exami-
nations for malaria parasites and intestinal helminth eggs
were carried out as described previously.10
Statistical analysis. Viral loads and infection intensities
were normalized by log10 transformation. The two sample
Students t test was used to analyze for differences in means,
and the 2 test for differences in prevalences between groups.
The effect of DEC treatment on HIV load, CD4%, and CD4/
CD8 ratio was analyzed according to standard procedures for
cross-over trials as described by Altman.18 Welch’s version of
the t test was used to test for treatment effect, period effect,
and treatment period interaction. No period effect and no
treatment period interaction were observed. A linear model
was fitted with the period differences as response and treat-
ment groups, infection status, and their interaction as predic-
tors; a significant interaction term means that the treatment
effect differs between the HIV+ and HIV+/CFA+ groups.
RESULTS
Infection status-eligible individuals were recruited from
May to June 2002. Collection of baseline data, randomization
and the first round of treatment occurred in June 2002. The
study participants were followed up at 1, 12, 13, and 24 weeks
after the first round of treatment. Cross-over was at 12 weeks
after the first treatment. We now describe the baseline char-
acteristics of the HIV-positive study participants (with or
without W. bancrofti co-infection) and the effect of DEC on
HIV load, CD4%, and CD4/CD8 ratio in these patients dur-
ing a 12-week period only, as there was no measurable effect
of DEC after 1 week. There were no adverse events or side
effects related to treatment among the study participants.
Characterization of the study groups. Among the 27 HIV-
positive study participants, 10 (37%) were males (Table 1).
The mean age was 41 (range 22–70) years, and there was no
significant difference in age between males and females. The
mean HIV load was 3.71 log units, and the mean CD4% was
27.3. CFA was present in 12 (44%) individuals, and their
mean intensity was 33,287 antigen units. P. falciparum was
found in 5 individuals (19%) with a geometric mean intensity
of 134 parasite/L blood among those infected. Hookworm
eggs were found in 13 (62%) of 21 examined individuals
(stool samples were not obtained from 6 individuals) with a
geometric mean intensity of 410 eggs per gram (epg) of feces
among those infected. Eggs from A. lumbricoides and Schis-
tosoma mansoni were not found in any of the study individu-
als, and T. trichiura eggs were found in 1 only. There was no
significant sex difference in the prevalence and intensity of
CFA, P. falciparum, or hookworm infection. When the 27
study participants were divided into two groups, with and
without filarial co-infection, the prevalence of hookworm was
63.3% and 60.0% (P  0.86), respectively, and the preva-
lence of P. falciparum was 27.3% and 13.3% (P  0.37),
respectively.
Effect of DEC treatment on HIV load. The individual HIV
load levels at 12 and 24 weeks follow-up in individuals with
(CFA+) or without (CFA−) filarial co-infection, are presented
in Figure 2. The effect of DEC on viral load was first assessed
in all HIV-positive individuals, disregarding filarial status
(CFA+/CFA−, N  26), and subsequently in individuals with
(CFA+, N  11) or without (CFA−, N  15) filarial co-
infection, separately. One sample could not be amplified in
TABLE 1
Background characteristics of the 27 HIV-positive study individuals
Age, in years* 41 (± 13)
Males (%) 37
HIV load (geq/mL)† 3.71 (± 0.97)
CD4%* 27.3 (± 11.4)
Circulating filarial antigen (CFA)
Positives, in % 44
Intensity, in CFA units* 33,287 (± 87,519)
P. falciparum
Positives, in % 19
Intensity, in parasites/L‡ 134 (5)
Hookworm
Positives, in %§ 62
Intensity, in epg 410 (5)
* Mean (± standard deviation).
† Mean intensity (± standard deviation) expressed as log10 viral load (genome equivalents
[geq] per mL) in serum from 26 individuals (HIV RNA could not be amplified in one
sample).
‡ Intensity expressed as geometric mean (5 is the standard deviation which should be
interpreted as a factor: intensities between 26.8 and 670) malaria parasites/L of infected
individuals only (n  5).
§ n  21, as stool samples were not obtained from 6 individuals.
 Intensity expressed as geometric mean (5 is the standard deviation which should be
interpreted as a factor: intensities between 82 and 2,050) eggs per gram of feces in infected
individuals only (n  13).
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PCR but tested positive in 2 different HIV field tests10 and
was omitted from the HIV load analyses.
The overall analysis among the HIV-positive individuals
(CFA+/CFA−) showed no significant treatment effect on HIV
load (0.059 log unit increase ≈ 15% [95% confidence interval
{CI}: −0.22; 0.34], P  0.66). However, when the results were
stratified by filarial status, an effect was observed in both
groups (Figure 3A). In the CFA+ group, a significant reduc-
tion in HIV load (−0.34 log unit [95% CI: −0.637; −0.048],
P  0.03), equaling 54%, was observed. In contrast, a 0.36 log
unit increase in HIV load (0.36 log unit [95% CI: −0.10; 0.82],
P  0.11), which equals a doubling (2.3 times the pretreat-
ment level), was observed in the CFA− group, but the in-
crease was not statistically significant. When the effect of
DEC on HIV load was compared in the CFA+ and CFA−
groups, it was shown to be significantly different (P  0.007).
Effect of DEC treatment on the CD4% and CD4/CD8 ra-
tio. The individual change in CD4% in the period between
the 12- and 24-week follow-up varied considerably (with both
increases and decreases observed), and given that day-to-day
variation may also occur, these data should be interpreted
with caution. The changes in CD4/CD8 ratio in the same
period were very small. Because of these facts, individual
changes in CD4% and CD4/CD8 ratio are not presented
graphically. Instead, the estimated mean effect of DEC on
CD4% and CD4/CD8 ratio is presented in Figure 3, B and C,
respectively. As with HIV load, the effect was first assessed in
all HIV-positive individuals (CFA+/CFA−, N  27) and then
in those with (CFA+, N  12) or without (CFA−, N  15)
filarial co-infection, separately. The overall analysis among
the HIV-positive individuals (CFA+/CFA−) showed no sig-
nificant change in CD4% (mean increase of 1.20% point
[95% CI: −2.24; 4.63], P  0.48) nor in the CD4/CD8 ratio
after treatment (mean increase of 0.08% point [95% CI:
−0.09; 0.25], P  0.36).
In the CFA+ group, the 12-week treatment effect on the
CD4% was an increase of 2.5% points (95% CI: −4.90; 9.94,
P  0.45), but the increase was not statistically significant
(Figure 3B). In the CFA− group, an insignificant effect (in-
crease of 0.12% point [95% CI: −3.41; 3.64], P  0.95) was
likewise observed. In contrast to HIV load, there was no sig-
nificant difference in the treatment effect in the two groups
(P  0.48).
The effect of DEC treatment on the mean CD4/CD8 ratio
was, as for the CD4%, small and statistically insignificant in
both the CFA+ and CFA− group with a mean increase in
FIGURE 2. Individual HIV load levels in HIV-positive individuals with (CFA+) or without (CFA−) W. bancrofti co-infection at 12 and 24 weeks
follow-up. The subfigure headings refer to the W. bancrofti infection status (CFA+ or CFA−) and the order in which DEC and placebo were given.
In 1 sample from the CFA+ group, HIV RNA could not be amplified in PCR; therefore this sample was omitted from the HIV load analyses.
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CD4/CD8 ratio of 0.15% point (95% CI: −0.24; 0.54, P 
0.38) and 0.01% point (95% CI: −0.10; 0.1, P  0.84), respec-
tively (Figure 3C). The treatment effect in the 2 groups was
not statistically different (P  0.37).
DISCUSSION
The present study analyzed the effect of DEC treatment on
HIV load, CD4%, and CD4/CD8 ratio over a 12-week follow-
up period in HIV-positive individuals with or without filarial
co-infection. Only individuals with asymptomatic infections
were included in the study to avoid confounding effects re-
lated to immunologic changes in the late stages of HIV infec-
tion and in chronic manifestations of filariasis. The pretreat-
ment survey showed a high prevalence of P. falciparum ma-
laria and hookworm infection in the study individuals.
The finding of a significant reduction in HIV load in the
HIV-positive individuals with filarial co-infection after treat-
ment indicates that DEC treatment reduces viral load in HIV
and filariae-positive individuals and may thus slow down the
progression of HIV. It seems likely that DEC acts through its
effect on the filarial infection. The mechanism behind this is
probably immunologically mediated, as treatment of the fi-
larial co-infection may result in a switch from a predominant
Th2-type response (known to be associated with filarial in-
fections19–21 and infections with other helminths5,22,23) to an
enhanced Th1-type response favorable in the combat against
HIV infection.4,24 Moreover, the reduction in viral load may
be related to a reduced level of immune activation, as anti-
filarial treatment may cause a reduction in activated T cells
and thereby reduce susceptibility to HIV and delay the viral
replication. The contrasting finding of an increase, though not
statistically significant, in HIV load among HIV-positive in-
dividuals without filarial infection may lead to the thought
that DEC could be harmful in terms of increasing HIV load.
However, the trend of an increase in CD4%, rather than a
decrease, in the same group of individuals does not lend sup-
port to this suspicion.
The difference in the effect of DEC on HIV load in indi-
viduals with and without filarial co-infection supports the idea
that DEC acts through its antifilaricidial properties rather
than through a direct (pharmacodynamic) effect on HIV load
in the dose applied in this study. However, it cannot be ex-
cluded that administration of DEC in a higher dose and/or for
a longer period of time could also have a direct effect on HIV
infection. Previous studies in cats have indicated that DEC
may have a direct effect on retroviral infections in cats,25,26
and DEC treatment (5 mg/kg body weight administered for
30 days) of HIV-infected humans in Guatemala intriguingly
showed that 5 out of 7 individuals, who tested positive for
HIV 1 p24 antigen before treatment, were negative (4 per-
sons) or had a lower (1 person) serum p24 value after 4 weeks
of treatment.27
The largest increase in CD4% after treatment was ob-
served in the CFA+ group, which corresponds well with the
significant decrease in HIV load in this group. The trend of an
increase in CD4%, rather than a decrease, in the HIV-
positive individuals without filarial infection indicates that
DEC had no harmful effect on the health of these patients. It
could be speculated that the time required for the treatment
effect to be reflected in the CD4% is longer than the follow-
up period, and the increase in CD4% after treatment might
have been bigger had the patients been followed up for a
longer time period. In addition, a higher dose of DEC may
have resulted in a more distinct increase in CD4%.
Generally, the change in the CD4/CD8 ratio after treat-
ment was small. A more pronounced increase in this ratio
might have been expected in the group of HIV-positive indi-
viduals with filarial co-infection after antifilarial treatment as
a result of the increased CD4%. However, because produc-
tion and activity of cytotoxic T cells (CD8 cells) appear to be
associated with a Th1-type response,5 an increase in the CD4/
FIGURE 3. Effect of DEC treatment on HIV load (A), CD4% (B), and CD4/CD8 ratio (C) in the CFA+ and CFA− groups 12 weeks after
treatment. Treatment effect is calculated according to the cross-over design as half the difference in the change over time between individuals
receiving treatment in the order placebo–DEC and DEC–placebo. Vertical bars represent standard error. In 1 sample from the CFA+ group, HIV
RNA could not be amplified in PCR; therefore this sample was omitted from the HIV load analyses (A).
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CD8 ratio may have failed to appear because the increase in
CD4 cells was accompanied by a simultaneous increase in
production of CD8 cells as a result of a switch from a Th2- to
a Th1-predominated response after treatment of the filariae.
In summary, the presented data suggest that DEC treat-
ment may have an important positive impact on the host’s
ability to respond to the HIV infection in individuals co-
infected with filariae and may thereby slow down the progres-
sion of HIV. The ongoing global efforts to control lymphatic
filariasis, which in many areas rely on annual mass treatment
with DEC, may thus have an additional beneficial effect in
terms of contributing to alleviation of the HIV/AIDS epi-
demic in areas where HIV and lymphatic filariasis co-exist. A
positive effect of DEC on HIV in W. bancrofti-endemic areas
may be even more pronounced if the drug was administered
at a higher dose and/or more frequently than once a year, a
perspective that deserves to be further investigated.
The prospects of DEC, being an inexpensive and well-
tolerated drug, as a tool in the combat against HIV/AIDS
may be even wider. If studies similar to the present study but
with 1) a higher dose of DEC, 2) continuous or regular ad-
ministration (contrary to the single dose in the present study),
3) larger study populations, and 4) longer follow-up periods
could provide indications of an anti-retroviral effect of DEC,
these might form the basis for development of new DEC-
based treatment strategies to combat HIV/AIDS. Studies on
the anti-retroviral efficacy of DEC (or DEC derivatives)
would also be of importance in attempts to be at the forefront
of potential development of resistance to the currently used
preparations.
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